Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Radiation Oncology
Published in: Radiation Oncology 1/2011

Open Access 01-12-2011 | Research

Stereotactic body radiotherapy for low-risk prostate cancer: five-year outcomes

Authors: Debra E Freeman, Christopher R King

Published in: Radiation Oncology | Issue 1/2011

Login to get access

Abstract

Purpose

Hypofractionated, stereotactic body radiotherapy (SBRT) is an emerging treatment approach for prostate cancer. We present the outcomes for low-risk prostate cancer patients with a median follow-up of 5 years after SBRT.

Method and Materials

Between Dec. 2003 and Dec. 2005, a pooled cohort of 41 consecutive patients from Stanford, CA and Naples, FL received SBRT with CyberKnife for clinically localized, low-risk prostate cancer. Prescribed dose was 35-36.25 Gy in five fractions. No patient received hormone therapy. Kaplan-Meier biochemical progression-free survival (defined using the Phoenix method) and RTOG toxicity outcomes were assessed.

Results

At a median follow-up of 5 years, the biochemical progression-free survival was 93% (95% CI = 84.7% to 100%). Acute side effects resolved within 1-3 months of treatment completion. There were no grade 4 toxicities. No late grade 3 rectal toxicity occurred, and only one late grade 3 genitourinary toxicity occurred following repeated urologic instrumentation.

Conclusion

Five-year results of SBRT for localized prostate cancer demonstrate the efficacy and safety of shorter courses of high dose per fraction radiation delivered with SBRT technique. Ongoing clinical trials are underway to further explore this treatment approach.
Appendix
Available only for authorised users
Literature
1.
Brenner DJ, Hall EJ: Fractionation and protraction for radiotherapy of prostate carcinoma. Int J Radiat Oncol Biol Phys. 1999, 43: 1095-1101. 10.1016/S0360-3016(98)00438-6.CrossRefPubMed
2.
Fowler JF, Ritter MA, Chappell RJ, Brenner DJ: What hypofractionated protocols should be tested for prostate cancer?. Int J Radiat Oncol Biol Phys. 2003, 56: 1093-1104. 10.1016/S0360-3016(03)00132-9.CrossRefPubMed
3.
Dasu A: Is the alpha/beta value for prostate tumours low enough to be safely used in clinical trials?. Clin Oncol (R Coll Radiol). 2007, 19: 289-301.CrossRef
4.
Macias V, Biete A: Hypofractionated radiotherapy for localised prostate cancer. Review of clinical trials. Clin Transl Oncol. 2009, 11: 437-445. 10.1007/s12094-009-0382-2.CrossRefPubMed
5.
Grills IS, Martinez AA, Hollander M, Huang R, Goldman K, Chen PY, Gustafson GS: High dose rate brachytherapy as prostate cancer monotherapy reduces toxicity compared to low dose rate palladium seeds. J Urol. 2004, 171: 1098-1104. 10.1097/01.ju.0000113299.34404.22.CrossRefPubMed
6.
Martinez AA, Demanes J, Vargas C, Schour L, Ghilezan M, Gustafson GS: High-Dose-Rate Prostate Brachytherapy: An Excellent Accelerated-Hypofractionated Treatment for Favorable Prostate Cancer. Am J Clin Oncol. 2010, 33 (5): 481-8. 10.1097/COC.0b013e3181b9cd2f.CrossRefPubMed
7.
Yoshioka Y, Konishi K, Oh RJ, Sumida I, Yamazaki H, Nakamura S, Nishimura K, Nonomura N, Okuyama A, Inoue T: High-dose-rate brachytherapy without external beam irradiation for locally advanced prostate cancer. Radiother Oncol. 2006, 80: 62-68. 10.1016/j.radonc.2006.06.011.CrossRefPubMed
8.
Aluwini S, van Rooij P, Hoogeman M, Bangma C, Kirkels WJ, Incrocci L, Kolkman-Deurloo IK: CyberKnife stereotactic radiotherapy as monotherapy for low- to intermediate-stage prostate cancer: early experience, feasibility, and tolerance. J Endourol. 2010, 24: 865-869. 10.1089/end.2009.0438.CrossRefPubMed
9.
Friedland JL, Freeman DE, Masterson-McGary ME, Spellberg DM: Stereotactic body radiotherapy: an emerging treatment approach for localized prostate cancer. Technol Cancer Res Treat. 2009, 8: 387-392.CrossRefPubMed
10.
Fuller DB, Naitoh J, Lee C, Hardy S, Jin H: Virtual HDR(SM) CyberKnife Treatment for Localized Prostatic Carcinoma: Dosimetry Comparison With HDR Brachytherapy and Preliminary Clinical Observations. Int J Radiat Oncol Biol Phys. 2008, 70: 1588-1597. 10.1016/j.ijrobp.2007.11.067.CrossRefPubMed
11.
Katz AJ, Santoro M, Ashley R, Diblasio F, Witten M: Stereotactic body radiotherapy for organ-confined prostate cancer. BMC Urol. 2010, 10: 1-10.1186/1471-2490-10-1.PubMedCentralCrossRefPubMed
12.
King CR, Brooks JD, Gill H, Pawlicki T, Cotrutz C, Presti JC: Stereotactic body radiotherapy for localized prostate cancer: interim results of a prospective phase II clinical trial. Int J Radiat Oncol Biol Phys. 2009, 73: 1043-1048. 10.1016/j.ijrobp.2008.05.059.CrossRefPubMed
13.
Madsen BL, Hsi RA, Pham HT, Fowler JF, Esagui L, Corman J: Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5 Gy in five fractions for localized disease: first clinical trial results. Int J Radiat Oncol Biol Phys. 2007, 67: 1099-1105. 10.1016/j.ijrobp.2006.10.050.CrossRefPubMed
14.
Townsend NC, Huth BJ, Ding W, Garber B, Mooreville M, Arrigo S, Lamond J, Brady LW: Acute toxicity after CyberKnife-delivered hypofractionated radiotherapy for treatment of prostate cancer. Am J Clin Oncol. 2010,
15.
Lloyd-Davies RW, Collins CD, Swan AV: Carcinoma of prostate treated by radical external beam radiotherapy using hypofractionation. Twenty-two years' experience (1962-1984). Urology. 1990, 36: 107-111. 10.1016/0090-4295(90)80207-4.CrossRefPubMed
16.
Hossain S, Xia P, Chuang C, Verhey L, Gottschalk AR, Mu G, Ma L: Simulated real time image guided intrafraction tracking-delivery for hypofractionated prostate IMRT. Med Phys. 2008, 35: 4041-4048. 10.1118/1.2968333.CrossRefPubMed
17.
Hossain S, Xia P, Huang K, Descovich M, Chuang C, Gottschalk AR, Roach M, Ma L: Dose gradient gear target-normal structure interface for nonisocentric CyberKnife and isocentric intensity-modulated body radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2010,
18.
Xie Y, Djajaputra D, King CR, Hossain S, Ma L, Xing L: Intrafractional motion of the prostate during hypofractionated radiotherapy. Int J Radiat Oncol Biol Phys. 2008, 72: 236-246. 10.1016/j.ijrobp.2008.04.051.PubMedCentralCrossRefPubMed
19.
Cox JD, Stetz J, Pajak TF: Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys. 1995, 31: 1341-1346. 10.1016/0360-3016(95)00060-C.CrossRefPubMed
20.
Abramowitz MC, Li T, Buyyounouski MK, Ross E, Uzzo RG, Pollack A, Horwitz EM: The Phoenix definition of biochemical failure predicts for overall survival in patients with prostate cancer. Cancer. 2008, 112: 55-60. 10.1002/cncr.23139.CrossRefPubMed
21.
D'Amico AV, Whittington R, Kaplan I, Beard C, Schultz D, Malkowicz SB, Tomaszewski JE, Wein A, Coleman CN: Equivalent 5-year bNED in select prostate cancer patients managed with surgery or radiation therapy despite exclusion of the seminal vesicles from the CTV. Int J Radiat Oncol Biol Phys. 1997, 39: 335-340.CrossRefPubMed
22.
D'Amico AV, Whittington R, Malkowicz SB, Cote K, Loffredo M, Schultz D, Chen MH, Tomaszewski JE, Renshaw AA, Wein A, Richie JP: Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era. Cancer. 2002, 95: 281-286.CrossRefPubMed
23.
D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, Tomaszewski JE, Renshaw AA, Kaplan I, Beard CJ, Wein A: Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. Jama. 1998, 280: 969-974.CrossRefPubMed
24.
Keyser D, Kupelian PA, Zippe CD, Levin HS, Klein EA: Stage T1-2 prostate cancer with pretreatment prostate-specific antigen level < or = 10 ng/ml: radiation therapy or surgery?. Int J Radiat Oncol Biol Phys. 1997, 38: 723-729. 10.1016/S0360-3016(97)00123-5.CrossRefPubMed
25.
Kupelian PA, Potters L, Khuntia D, Ciezki JP, Reddy CA, Reuther AM, Carlson TP, Klein EA: Radical prostatectomy, external beam radiotherapy <72 Gy, external beam radiotherapy > or = 72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1-T2 prostate cancer. Int J Radiat Oncol Biol Phys. 2004, 58: 25-33. 10.1016/S0360-3016(03)00784-3.CrossRefPubMed
26.
Martinez AA, Gonzalez JA, Chung AK, Kestin LL, Balasubramaniam M, Diokno AC, Ziaja EL, Brabbins DS, Vicini FA: A comparison of external beam radiation therapy versus radical prostatectomy for patients with low risk prostate carcinoma diagnosed, staged, and treated at a single institution. Cancer. 2000, 88: 425-432. 10.1002/(SICI)1097-0142(20000115)88:2<425::AID-CNCR25>3.0.CO;2-Z.CrossRefPubMed
27.
King CR, Brooks JD, Gill H, Presti JCJ: Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2010,
28.
Aizer AA, Yu JB, Colberg JW, McKeon AM, Decker RH, Peschel RE: Radical prostatectomy vs. intensity-modulated radiation therapy in the management of localized prostate adenocarcinoma. Radiother Oncol. 2009, 93: 185-191. 10.1016/j.radonc.2009.09.001.CrossRefPubMed
29.
Cahlon O, Zelefsky MJ, Shippy A, Chan H, Fuks Z, Yamada Y, Hunt M, Greenstein S, Amols H: Ultra-high dose (86.4 Gy) IMRT for localized prostate cancer: toxicity and biochemical outcomes. Int J Radiat Oncol Biol Phys. 2008, 71: 330-337. 10.1016/j.ijrobp.2007.10.004.CrossRefPubMed
30.
Grimm PD, Blasko JC, Sylvester JE, Meier RM, Cavanagh W: 10-year biochemical (prostate-specific antigen) control of prostate cancer with (125)I brachytherapy. Int J Radiat Oncol Biol Phys. 2001, 51: 31-40.CrossRefPubMed
31.
Han M, Partin AW, Pound CR, Epstein JI, Walsh PC: Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin North Am. 2001, 28: 555-565. 10.1016/S0094-0143(05)70163-4.CrossRefPubMed
32.
Kupelian PA, Thakkar VV, Khuntia D, Reddy CA, Klein EA, Mahadevan A: Hypofractionated intensity-modulated radiotherapy (70 gy at 2.5 Gy per fraction) for localized prostate cancer: long-term outcomes. Int J Radiat Oncol Biol Phys. 2005, 63: 1463-1468. 10.1016/j.ijrobp.2005.05.054.CrossRefPubMed
33.
Katz AJ, Santoro M: Quality of life and efficacy for stereotactic body radiotherapy for treatment of organ confined prostate cancer. Annual Meeting of the Association for Radiation Oncology. San Diego, CA. 2010
34.
Ponsky LE, Lillibridge C, Brindle J, Zhang Y, Wessels B, Einstein DB: Stereotactic robotic radiosurgery for localized prostate cancer: Initial evaluation of acute toxicities. 2009 ASCO Annual Meeting. Orlando, Florida. 2009
35.
Oermann E, Hanscom HS, Lei S, Suy S, Chen V, Collins BT, Dritschilo A, Lynch JH, Dawson NA, Collins SP: Hypofractionated robotic radiosurgery for the treatment of clinically localized prostate cancer: Early biochemical results and acute toxicity. 2010 ASCO Annual Meeting Chicago, IL. 2010
Metadata
Title
Stereotactic body radiotherapy for low-risk prostate cancer: five-year outcomes
Authors
Debra E Freeman
Christopher R King
Publication date
01-12-2011
Publisher
BioMed Central
Published in
Radiation Oncology / Issue 1/2011
Electronic ISSN: 1748-717X
DOI
https://doi.org/10.1186/1748-717X-6-3

Other articles of this Issue 1/2011

Radiation Oncology 1/2011 Go to the issue

Research

Current measures of metabolic heterogeneity within cervical cancer do not predict disease outcome

Research

Disease control and functional outcome in three modern combined organ preserving regimens for locally advanced squamous cell carcinoma of the head and neck (SCCHN)

Methodology

Survival Analysis of F98 Glioma Rat Cells Following Minibeam or Broad-Beam Synchrotron Radiation Therapy

Research

Clinical Analysis of stereotactic body radiation therapy using extracranial gamma knife for patients with mainly bulky inoperable early stage non-small cell lung carcinoma

Study protocol

Feasibility and early clinical assessment of flattening filter free (FFF) based stereotactic body radiotherapy (SBRT) treatments

Research

Impact of pathological tumor stage for salvage radiotherapy after radical prostatectomy in patients with prostate-specific antigen < 1.0 ng/ml